Dr. gordana raca from children's hospital los angeles presents findings that show saphyr detects druggable gene fusions in pediatric acute leukemias that ngs and cytogenetics missed

San diego, jan. 29, 2021 (globe newswire) -- bionano genomics, inc. (nasdaq: bngo) announced a presentation by the director of the clinical cytogenomics laboratory of children's hospital los angeles, dr. gordana raca, in which she reported on the performance of optical genome mapping (ogm) for the clinical analysis of pediatric acute leukemias. she demonstrated how ogm with saphyr detected clinically important structural variants (svs) that can alter patient care and treatment decisions. these svs were not detected when the samples were evaluated with a combination of next-generation sequencing (ngs) and three cytogenetic methods that are the standard of care in leukemia testing today. she concluded that ogm would be advantageous in clinical testing because it detects all types of svs but with better precision, higher resolution and better sensitivity than traditional methods, including next generation sequencing (ngs).
BNGO Ratings Summary
BNGO Quant Ranking